Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364946 | 0.88 | DRD4 (0.43) | HPGDSSRCDRD2DRD4F10 | |
| SCHEMBL1367373 | 0.84 | HPGDS (0.41) | HPGDSSRCDRD2DRD4GABRA5 | |
| SCHEMBL16496076 | 0.81 | HPGDS (0.54) | HPGDSSRCDRD2DRD4WNT3A | |
| SCHEMBL16495666 | 0.80 | HPGDS (0.55) | HPGDSSRCDRD2DRD4WNT3A | |
| SCHEMBL1366736 | 0.80 | HPGDS (0.44) | HPGDSSRCDRD2DRD4HDAC1 | |
| SCHEMBL1364881 | 0.79 | HPGDS (0.41) | HPGDSSRCDRD2GABRA5 | |
| SCHEMBL16496171 | 0.78 | HPGDS (0.53) | HPGDSSRCDRD2DRD4WNT3A | |
| SCHEMBL2073286 | 0.75 | HPGDS (0.68) | HPGDSDRD2DRD4CCR3 | |
| SCHEMBL1364506 | 0.73 | HPGDS (0.42) | HPGDSDRD2DRD4 | |
| SCHEMBL16495485 | 0.73 | SRC (0.50) | HPGDSSRCDRD2DRD4F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885BDKRB1 153/4885SRC 3330/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885BDKRB1 153/4885SRC 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.